Ivermectin, identified by CAS number 70288-86-7, is a complex macrocyclic lactone that has revolutionized antiparasitic treatments. Chemically, it is a mixture of at least two closely related compounds, primarily Ivermectin B1a and Ivermectin B1b. These compounds are derived from avermectin, a product of the soil actinomycete Streptomyces avermitilis. The molecular formula for Ivermectin B1a is C48H74O14, with a molecular weight of approximately 875.1. It typically presents as a white to yellowish-white crystalline powder, with solubility in organic solvents like DMSO and ethanol.

The quality and consistency of Ivermectin are paramount, especially given its application as an Active Pharmaceutical Ingredient (API). The Ivermectin production process adheres to stringent Good Manufacturing Practice (GMP) standards. These standards ensure that the drug is consistently produced and controlled according to quality appropriate to its intended use and as required by the marketing authorization. This includes rigorous testing for purity, identity, and the absence of impurities. Regulatory bodies worldwide set specifications for Ivermectin, often referencing pharmacopeial standards such as USP (United States Pharmacopeia), EP (European Pharmacopoeia), or BP (British Pharmacopoeia).

The regulatory landscape for pharmaceuticals like Ivermectin is complex, requiring thorough documentation and adherence to various guidelines. Manufacturers must ensure traceability throughout the supply chain, from raw material sourcing to final product release. Companies like NINGBO INNO PHARMCHEM CO.,LTD. focus on meeting these exacting standards to provide reliable pharmaceutical ingredients for global markets. Understanding the chemical properties and the regulatory framework surrounding Ivermectin is essential for its safe and effective use in both human and veterinary medicine, as well as for ongoing research into its expanded therapeutic potential.